Introduction: Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimer's disease (AD) diagnosis. Postsynaptic protein neurogranin may be a promising cerebrospinal fluid (CSF) biomarker but has not yet been evaluated as a plasma biomarker. Methods: Using an in-house designed prototype enzyme-linked immunosorbent assay (ELISA) targeting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls (n 5 29) versus patients experiencing MCI, or dementia, due to AD (in total n 5 59). Results: CSF neurogranin was increased in AD and positively correlated with CSF tau, whereas there was a negative relationship between CSF neurogranin (and tau) and CSF Ab 1-42 /Ab . No differences were detected in plasma neurogranin between controls and AD. Also, there was no correlation between CSF and plasma neurogranin, excluding confounding effects of the latter. Discussion: This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immunoassays can be used, as demonstrated by the described ELISA.
Background
There is a need for improved early diagnosis of Alzheimer's disease (AD), especially in stages before dementia onset. Current parameters, such as the cerebrospinal fluid (CSF) biomarkers tau and Ab , are highly predictive for the imminent occurrence of AD but have poor prognostic value regarding onset of cognitive decline [1] . From a neuropathologic perspective, the link between cognitive decline and tau/tangle or amyloid/plaque pathology seems complex [2] . Because the loss of brain synapses is much closer related to cognitive decline [3, 4] , a synaptic CSF biomarker could thus improve the prognostic accuracy of the AD biomarker panel.
Gained insights on neurogranin suggest that this postsynaptic protein could be a surrogate biomarker for synaptic loss. Neurogranin is important for long-term potentiation and learning abilities, mostly through interaction with calmodulin [5] , and is found in CSF under physiological conditions [6] [7] [8] . Interestingly, in AD, neurogranin levels are decreased in the brain [9, 10] , whereas CSF levels are elevated as shown in our pilot study using immunoprecipitation and semiquantitative immunoblotting [11] . Recently, the ADrelated increase in CSF neurogranin levels, which were moreover correlated with CSF tau concentrations, was verified by an enzyme-linked immunosorbent assay (ELISA) based on a new monoclonal antibody (mAb). Furthermore, the elevated neurogranin levels correlated with cognitive decline in prodromal AD [12] . These findings clearly support the potential of neurogranin as an AD CSF biomarker and warrants further studies. Finally, there is emerging evidence that neurogranin is also circulating in blood in the ng/mL range [13, 14] . However, whether neurogranin could also be considered as an AD plasma biomarker has not been investigated up to date. Accordingly, straightforward, yet highly specific, robust tools are required for further studies, allowing accurate measurements of neurogranin. In detail, hybrid immunoaffinitymass spectrometry revealed CSF neurogranin as a pool of predominantly C-terminal peptides, whereas the full-length sequence was only present in minor quantities [12] . Targeting specific metabolic fragments is suggested to improve diagnostic performance of immunoassays, as demonstrated for tau of which predominantly N-terminal and mid-domain fragments are distinguished in CSF [15] . Therefore, we aimed to develop an ELISA during this study specific for the C-terminal part of neurogranin. Additionally, using this new prototype assay, we assessed neurogranin as a biomarker in CSF and plasma during an explorative study in paired CSF/plasma samples, collected from participants covering the whole disease spectrum of AD, from cognitively normal to experiencing full-blown dementia. The relationship between neurogranin and available clinical parameters, e.g. MiniMental State Examination (MMSE), was considered during the analysis as well as the link with the classical AD CSF biomarkers, e.g. CSF tau, but also plasma tau. Recent work demonstrated no correlation between tau levels in CSF and plasma [16] . By selecting a subgroup of patients with very high CSF tau levels, we wanted to confirm this observation and extend it by also investigating the relationship between neurogranin and tau in CSF/plasma. Finally, because the ratio CSF Ab 1-42 /CSF Ab 1-40 appears to perform diagnostically better than the levels of the single analyte CSF Ab [17] , we investigated the relationship between CSF neurogranin and CSF Ab 1-42 /CSF Ab 1-40 .
Methods

Study population
CSF/plasma samples from patients recruited in the Memory Clinic and Department of Neurology of Hospital Network Antwerp were selected from the Biobank of Institute Born-Bunge (Antwerp, Belgium). Patients with MCI due to AD (referred to as "MCI" hereafter) (n 5 20), dementia due to AD ("AD") (n 5 20), and patients with MCI or AD with high CSF T-tau levels ("high tau") (n 5 20) were included. Diagnosis was based on the National Institute on Aging-Alzheimer's Association criteria [18, 19] , whereby CSF biomarkers Ab 1-42 , T-tau, and P-tau 181P were analyzed at the Institute Born-Bunge using commercial kits (INNOTEST b-AMYLOID , INNOTEST hTAU-Ag, and INNOTEST PHOSPHO-TAU (181P) ; Fujirebio Europe; Belgium) and whereby the institute's cutoff values were applied to discriminate AD from controls [20] . All patients had high probability of AD etiology except for one MCI patient who had intermediate probability. Also, one MCI patient carried a PSEN1 mutation. The "high tau" group included MCI (n 5 2) and AD (n 5 18) patients demonstrating CSF T-tau levels .1200 pg/mL. Regarding the participants of the control group ("CTRL") (n 5 30), cognitive deterioration was ruled out by neuropsychological screening, as well as neurologic or psychiatric antecedents, or central nervous system disorders. The study was approved by the local ethics committee (University of Antwerp). All subjects gave written informed consent. CSF samples were obtained by lumbar puncture (LP) at the L3/L4 or L4/L5 interspace, collected in polypropylene tubes, and immediately frozen in liquid nitrogen. Plasma samples were collected immediately after LP, centrifuged at room temperature (RT) (10 min, 3000 rpm), transferred to polypropylene tubes, and immediately frozen in liquid nitrogen. Both types of samples were stored at 280 C until analysis.
From one-third of the participants, brain magnetic resonance imaging scans were available. The hippocampal volume (HCV) was visually rated by two radiologists, separately, blinded for diagnosis [21] . If needed, a consensus rate on divergent rates was discussed. On some participants APOE genotyping was performed. The single nucleotide polymorphisms in APOE-rs429358 and rs7412-determining the ε2/ε3/ε4 polymorphism were genotyped by Sanger sequencing starting from genomic DNA extracted from lymphocytes.
Neurogranin ELISA for CSF and plasma
Ninety-six well microtiter plates were coated with mAb Ng7 in phosphate-buffered saline (PBS), for 1 h at RT. After washing with PBS containing 0.05% Tween-20 (PBST), the plates were blocked with blocking reagent (PBS; 0.5% casein; 0.05% ProClin; 2 h at RT). The calibrator, synthetic full-length neurogranin (custom-made by ProteoGenix, France) was prepared in sample diluent (SD; PBS; 0.1% casein; 0.4% Triton; 0.05% ProClin) at an initial concentration of 2000 pg/mL and subsequent fourfold dilutions were made. Samples (CSF undiluted; plasma 1:16 in SD) and calibrator dilutions were simultaneously incubated overnight at RT with the polyclonal antibody (pAb) 07-425 (cat nr 07-425; Merck Millipore, USA) in SD. After washing, horseradish peroxidase (HRP)-conjugated donkey anti-rabbit Ab (diluted 1:2.500 in conjugate diluent, PBS; 0.1% casein; 0.05% ProClin) was added. After incubation for 1 h at RT, the plates were washed and 3,3 0 ,5,5 0 -Tetramethylbenzidine solution was added to engage development. After 30 min at RT, the colouring reaction was stopped with 1 M sulfuric acid and plates were read spectrophotometrically in a BioTek microplate reader, at 450 nm (630 nm as reference wavelength). Neurogranin levels were calculated via interpolation (log/log; 4PL weighted 1/Y 2 ) based on the calibrator curve.
Tau ELISA for plasma
Ninety-six well microtiter plates were coated overnight with mAb 77E9 (cat nr MMS-5018; Covance, USA) in PBS, at 2 C-8 C. After washing with PBST, the plates were blocked with blocking reagent for 2 h at RT. As calibrator, Escherichia coli recombinant tau441 (cat nr T-1001-1; rPeptide, USA) was prepared in sample buffer (SB; PBS; 0.1% casein; 0.4% Triton; 0.05% ProClin; blue coloring reagent) at an initial concentration of 1200 pg/mL and subsequent threefold dilutions were made. Undiluted plasma samples and calibrator dilutions were simultaneously incubated with biotinylated mAb ADx215 in SB (3 h, RT). After washing, polyHRP-conjugated streptavidin (SDT; Germany) diluted 1:2.500 in SD was added and incubation of 30 min at RT followed. Plates were washed, and the same development protocol was followed as for neurogranin. Tau levels were calculated via interpolation (log/log; 4PL weighted 1/Y 2 ) based on the calibrator curve. However, because this research assay is not yet fully developed, the quantifications are expressed as arbitrary units (AU).
2.4.
ELISA for the CSF biomarkers total-tau, Ab , and Ab Based on recent work [15] , we chose to measure CSF tau with the total-tau kit by EUROIMMUN (Germany). This assay measures the N-terminal part of CSF tau, in contrast to the INNOTEST hTAU-Ag assay targeting fragments from the proline-rich region. Additionally, the total-tau kit enables quantification of tau levels above 1200 pg/mL, contrary to the INNOTEST, because it sets the highest calibrator at 1462 pg/mL. This enabled us to also accurately quantify CSF tau in the "high tau" group.
For the quantification of CSF Ab 1-42 and CSF Ab 1-40, we used the b-Amyloid (1-42) ELISA and b-Amyloid (1-40) ELISA by EUROIMMUN. The former assay has been optimized to ensure reproducible clinical results, in contrast to INNOTEST b-AMYLOID [22] . All three European Conformity (CE)-certified assays by EUROIMMUN (CSF total-tau, CSF Ab , and CSF Ab 1-40 ) were performed according to the kit-insert, using the lyophilized, ready-to-use calibrators and standardized protocols.
Statistical analysis
Statistical analyses were performed using SPSS 20.0 for IBM, and R version 3. 
Results
Analytical characteristics of the neurogranin assay
The research prototype neurogranin ELISA described in this study involved two Abs targeting the C-terminal part of neurogranin: a capture mouse mAb, i.e. Ng7, and a detector rabbit pAb, defined as "07-425" throughout this article. The generation of Ng7 is described elsewhere [12] , whereas 07-425 is commercially available by Merck Millipore. To verify the C-terminal epitope of both Abs, epitopemapping was performed with eight biotinylated synthetic peptides (14-mers), covering the sequence R 51 -D 78 and overlapping each other with 12 amino acids. The epitope of Ng7 was confirmed as targeting aa53(R)-64(A) of neurogranin (Fig. 1) . The epitope of 07-425 encompasses aa66(V)-78(D), downstream from the Ng7 epitope, allowing both Abs to be combined in a two-site ELISA format. To evaluate the sensitivity of this set-up, three CSF samples with low endogenous neurogranin levels were run in 10 replicates and the lowest concentration that could be quantified, based on the standard curve (in duplicate), with a coefficient of variation of 20% was 3 pg/mL. The standard curve consisted of fourfold serially dilutions (2000-0.12 pg/mL) of synthetic full-length neurogranin (aa1-78), as calibrator. Eventually, the range of the resulting immunoassay, i.e. 3-2000 pg/mL, covered 86% of undiluted CSF samples and 76% of 16-fold diluted plasma samples during the study.
Because both Ng7 and 07-425 target the collagen-like region of neurogranin (homology scoring between collagen and this domain ranges from 39 to 55% [aa identity]) and because collagen is an abundant protein in the human brain and vascular system [23] [24] [25] , cross-reactivity was addressed of both Abs on a few human collagen types, i.e. type I, III, and IV. Ng7 did not display any crossreactivity in Western blotting or one-site as well as twosite ELISA nor did 07-425 ( Supplementary Figs. 1 
Levels of CSF neurogranin in different diagnostic groups
Four assays were run on the CSF samples, blinded from clinical diagnosis: the research ELISA to measure neurogranin as well as three commercial ELISAs (EUROIMMUN) for CSF total-tau, CSF Ab , and CSF Ab . Subsequently, one sample from the CTRL group, demonstrating extremely low CSF Ab 1-40 (22 pg/mL), was excluded. Also, one sample from the high tau group was omitted because the high CSF T-tau levels, based on the INNOTEST hTAU-Ag test, could not be confirmed (133 pg/mL). It should be pointed out that in case CSF neurogranin levels were below the assay's lower limit of quantification (LLOQ), i.e. 3 pg/mL, values were equaled to LLOQ/2. NOTE. CSF samples were analyzed using the research prototype ELISA for neurogranin and three commercially available assays (total-tau ELISA for CSF total-tau, b-Amyloid (1-42) ELISA for CSF-Ab , and b-Amyloid (1-40) ELISA for CSF-Ab 1-40 ; EUROIMMUN, Germany). Plasma samples were studied using the same ELISA for neurogranin on the one hand and a research prototype tau ELISA on the other hand. The groups were not age or gender matched. All data are median values with 25th and 75th quartiles, except for n. For details on statistical analyses, see "Methods."
NOTE. summarizes the levels of all analytes, combined with the demographic and clinical data of the population.
CSF neurogranin levels differed noticeably between the diagnostic groups (Table 1 and Fig. 2A) . Compared with the CTRL group, CSF neurogranin concentrations were significantly increased in MCI (P , .001; Cohen's d 5 1.06), AD (P , .001), and in subjects having high tau levels (P , .001).
The relationship between CSF neurogranin and CSF totaltau, CSF Ab 1-42, and CSF Ab 1-40 , of which group levels are shown in Fig. 2 , was also addressed. When calculating the Spearman correlation coefficients, the MCI, AD, and high tau groups were pooled because of the low number of participants (n) in each individual diagnostic group. Table 2 summarizes the correlation between the analytes in the CTRL group versus this pooled AD group. CSF neurogranin and CSF total-tau were strongly correlated in both controls (r 5 0.713; P , .001) and AD patients (r 5 0.624; P , .001). Between CSF neurogranin and CSF Ab (r 5 0.498; P , .01) and Finally, although CSF neurogranin and age correlated in the CTRL group (Supplementary Table 2 ), including age, and gender, as covariate in the regression analysis excluded possible confounding effects of age, and gender, on the differences in CSF neurogranin between groups (Supplementary Fig. 3 ). Besides age, no correlations were observed between CSF neurogranin and clinical parameters, such as MMSE scores (at the time of LP) nor the change in MMSE per year or disease duration (Supplementary Table 2 , Supplementary Fig. 4 ). Also, no correlations could be detected between CSF neurogranin and apolipoprotein E (APOE) ε4 alleles or the albumin CSF/serum ratio. A weak nonsignificant correlation was noted with HCV (r 5 20.302) in case of the AD groups. One correlation was found for CSF total-tau, in AD, with HCV (r 5 20.523; P , .05).
Relationship neurogranin and tau in paired plasma/ CSF samples
Paired plasma samples of the patients involved in the CSF study were also examined, revealing levels of plasma neurogranin in the ng/mL range (0.04-2.33 ng/mL; 25th-75th percentiles). Using an in-house assembled research ELISA, we were able to measure tau in 98% of these plasma samples as well. As summarized in Table 1, there were no statistically significant differences in plasma neurogranin between the diagnostic groups nor did the plasma levels correlate with the amounts in CSF (Fig. 3A) . Similarly, there were no substantial differences in tau levels between the groups neither did the levels of tau correlate in CSF and plasma (Fig. 3B) . Also, unlike in CSF (Fig. 3D ), neurogranin and tau did not correlate in plasma (Fig. 3C) . Remarkably, CSF total-tau did significantly, although weakly, correlate with plasma neurogranin (r 5 20.272, P , .05).
Finally, there was no correlation between plasma neurogranin (or tau) and MMSE at LP, MMSE change per year Table 2  Correlation matrix NOTE. To determine the Spearman's correlation coefficients, represented by the rho-values in the table, the groups of MCI, AD, and MCI or AD with high CSF tau levels were pooled because of the low n in each group separately in this explorative study. The resulting pooled group is referred to as "AD patients" in the top of the table. For details on statistical analyses, see "Methods."
NOTE. *P , .05; **P , .01; and ***P , .001. or disease duration nor with the albumin CSF/serum ratio or HCV rating (Supplementary Table 3 ).
Discussion
The need for thoroughly characterized molecular assays has been recently demonstrated for the classical AD biomarker CSF tau. Apparently, CSF tau occurs predominantly as a series of N-terminal and mid-domain fragments. Consequently, immunoassays targeting specifically N-terminal and mid-domain tau fragments are diagnostically valuable [15] . Regarding neurogranin, using mass spectrometry, the protein is detected in CSF as several C-terminal fragments, whereas only minor quantities of full-length neurogranin are present [12] . Therefore, we designed an ELISA based on the mAb Ng7 and a commercial pAb, both targeting neurogranin C-terminally, in the collagen-like domain of the protein. Notably, cross-reactivity of both Abs toward some abundant types of collagen, i.e. type I, III, and IV, was excluded. However, the assay still needs further refinement. Optimally, additional, well-defined monoclonal antibodies are developed that can supplementary add specificity to the assay. Mass spectrometry identified 15 different C-terminal peptides of neurogranin in CSF [12] . Some of these peptides end at the last amino acid of neurogranin, i.e. aa78, but others end at aa76, 75, or 65. The pAb used in this study specifically targets an intact C-terminus, so it would not detect truncated C-terminal fragments ending at aa76 or less. Apart from C-terminal truncation, there are other posttranslational modifications of neurogranin as well [26] [27] [28] , such as phosphorylation at S36, recognized to be associated with memory. Finally, although the current ELISA enables analysis of neurogranin in all patients, the analytical sensitivity needs to be increased, allowing quantification in all samples, particularly control samples where neurogranin concentrations are low.
Although neurogranin is predominantly found in brain cortical regions [29] , plasma proteomics efforts unequivocally demonstrate neurogranin in the blood, even in the ng/mL concentrations [13] . Reported possible sources are based on transcriptional data, blood platelets [30] , and lymphocytes [31] , or, as e.g. demonstrated by immunohistochemistry, endothelial cells [32, 33] . Our study indeed confirmed levels of neurogranin in a range of ng/mL, corroborating most recent findings based on immunodetection [14] . However, in plasma, no significant differences in mean neurogranin levels between diagnostic groups were seen neither were the plasma levels correlated with CSF levels. Using an in-house designed sensitive ELISA, we made similar observations with tau. While tau levels were lower in plasma than in CSF, mean plasma levels between the different groups did not differ and CSF-plasma levels were not correlated. This is in line with earlier studies where plasma tau did not differ between control, MCI, or AD patients [16] . Combined, it suggests that the relationship between the levels of a particular analyte in CSF and plasma is not straightforward or that valuable CSF biomarkers are not necessarily valuable as plasma biomarker. It is possible that changes in plasma levels only occur in advanced stages of AD, with extensive neurodegeneration, as already suggested for tau [16] . Especially regarding neurogranin, early, minor pathologic changes in plasma levels are possibly undetectable due to the high physiological levels. Nonetheless, these high concentrations in the blood do not seem to affect CSF levels of neurogranin, excluding possible confounding effects and affirming CSF neurogranin as potential CSF AD biomarker.
During this explorative clinical study, a highly significant correlation between CSF neurogranin and CSF tau levels was noted, as previously described [11, 12] . Although tau is a well-established axonal protein, recent reports located tau also in synapses, in both normal and AD brain [34] [35] [36] . Because CSF tau and CSF neurogranin correlate strongly, they possibly both reflect synaptic damage. However, in a recent confirmatory longitudinal CSF study on AD, no change in CSF tau was detected in contrast to three of four longitudinal dynamic biomarkers related to synaptic integrity, e.g. chromogranin, and which were also highly correlated with CSF tau [37] . This suggests that synaptic desintegrity, reflected by increased CSF levels of these synaptic proteins, might occur earlier than structural degenerations mirrored by CSF tau. Additionally, the current CSF biomarker panel, including CSF tau, lack prognostic value regarding onset of cognitive deterioration [1] . Although in the present study the potential of neurogranin as CSF biomarker to discriminate AD from cognitively normal has been confirmed, the prognostic value now needs to be fully validated. Specifically, although a link was observed between neurogranin and cognitive decline in a previous study [12] , no correlations with cognitive markers, such as (change in) MMSE and semiquantitative measurements of brain atrophy, reached statistical significance in the present study. On the other hand, this might be due to the exploratory, retrospective nature of the study, involving relatively small patient groups and a not yet fully developed ELISA. To resolve this issue, larger clinical studies will be designed to validate the prognostic value of neurogranin. These verification studies will involve a refined ELISA and include well-defined patients groups as well as age-matched controls, all with clinical and neuropsychological follow-up.
During the study, a correlation between CSF neurogranin, and also tau as expected [38] , was noted with CSF Ab , in both the control and AD groups. Remarkably, neither CSF neurogranin nor tau correlated with CSF Ab in AD. Further analysis, however, showed a negative correlation between CSF neurogranin and the CSF Ab 1-42 /CSF Ab 1-40 ratio. Because this negative correlation was also observed in the case of CSF tau (confirmed by unpublished clinical studies), these data link synaptic and/or axonal loss to altered Amyloid Precursor Protein (APP) metabolism for the first time. In cellular and animal models for AD, CSF Ab 1-42 / CSF Ab 1-40 has already been studied in relation to g-secretase dysfunction [39] , which corroborates a study in human brain tissue and CSF [40] . Furthermore, recent studies using CSF Ab 1-42 /CSF Ab 1-40 point toward better diagnostic performance than CSF Ab [17, 41] . Perhaps this is related to the accuracy of measuring the Ab analytes separately. Especially CSF Ab 1-42 is affected by many confounding factors [42] . Recent advancements in mass spectrometry analysis of CSF Ab peptides could, however, help in measuring this ratio more precisely [43, 44] . In combination with second generation immunoassays, this would allow to further explore the link between synaptic/ axonal loss and g-secretase dysfunction.
In conclusion, using two C-terminal anti-neurogranin antibodies, highly specific for the collagen-like domain of the protein, we were able to quantify C-terminal neurogranin in plasma and CSF, with an analytical sensitivity of 3 pg/mL, with synthetic full-length neurogranin as a calibrator. During this explorative study, the potential of neurogranin as a CSF biomarker for AD has been confirmed which inspires us to design larger clinical, longitudinal studies to further substantiate the probable diagnostic and/or prognostic value of CSF neurogranin. As tools, straightforward immunoassays can be used, as demonstrated by the described ELISA.
